Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

This study is testing whether combining chemotherapy and immunotherapy (a treatment that helps the immune system fight cancer) before surgery can be effective for women with early-stage cervical cancer (stage IB2). The goal is to shrink the tumor before performing a hysterectomy (surgical removal of the uterus). **You may be eligible if...** - You are 18–70 years old with untreated stage IB2 cervical cancer - Your cancer is confirmed as squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma - Your tumor tests positive for a protein called PD-L1 (CPS score of 1 or higher) - You have at least one measurable tumor on imaging - You are in good general health (ECOG score 0–1) with adequate blood, liver, and kidney function **You may NOT be eligible if...** - You have other types or stages of cervical cancer - Your tumor does not express PD-L1 - You have significant heart, liver, kidney, or blood problems - You have a history of autoimmune disease or prior immunotherapy Talk to your doctor to see if this trial is right for you.